We’re proud to announce the second peer-reviewed publication of our Phase 1 study on 3-MMC, is now published in Psychopharmacology. This follow-up paper dives deeper into the analgesic effects and mood-related outcomes of 3-MMC in healthy volunteers.
Study Highlights
- Design: Double-blind, placebo-controlled, cross-over
- Participants: 14 healthy individuals
- Dosages: 25 mg, 50 mg, 100 mg
- Measures: Pain threshold (PPT), cold pressor test (CPT), mood, side effects
What We Found
Pain relief: Dose-related increases in pain threshold and tolerance
Mood enhancement: Positive mood effects peaking 1 hour post-dosing
Safety: No severe side effects reported — mild and transient adverse events only
Key Statement from the Publication:
“This seems to suggest that the adverse event profile of 3-MMC is benign at low to moderate doses which might increase opportunities for medical use of 3-MMC in the treatment of pain. Given its mood enhancing property, 3-MMC might also provide a potential treatment for mental health disorders related to pain such as premenstrual dysphoric disorder (PMDD).”
Why This Matters
Pain and mood are deeply intertwined — particularly in conditions like PMDD, which affect millions of women but remain underserved by innovation.
This publication strengthens our commitment to:
- Exploring safe, evidence-based applications of psychoactive compounds
- Designing research that prioritizes the complex realities of women’s health
- Opening the door for new therapeutic possibilities where few exist today
Read the Full Publication
https://link.springer.com/